Ligand Pharmaceuticals (NASDAQ:LGND) Shares Break Below 50 Day Moving Average After Insider Selling

Ligand Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Shares slipped below the 50-day moving average, trading as low as $300.55 versus the average of $302.03, amid recent director sales. Three directors sold shares, including 2,000 shares by Martine Zimmermann and 3,000 by Jason Aryeh.
  • Analysts maintain a Moderate Buy consensus, with eight Buy ratings and one Hold; the average price target is $355.38. Recent targets include Citigroup’s $402 and RBC’s $357.
  • Ligand beat quarterly estimates, reporting EPS of $2.67 versus $2.33 expected and revenue of $78.75 million versus $77 million expected, though revenue fell 31.8% year over year.
  • MarketBeat previews top five stocks to own in December.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) shares crossed below its 50 day moving average during trading on Monday following insider selling activity. The stock has a 50 day moving average of $302.03 and traded as low as $300.55. Ligand Pharmaceuticals shares last traded at $301.71, with a volume of 187,061 shares changing hands.

Specifically, Director Martine Zimmermann sold 2,000 shares of Ligand Pharmaceuticals stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $318.17, for a total value of $636,340.00. Following the transaction, the director owned 1,782 shares in the company, valued at $566,978.94. This trade represents a 52.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John Kozarich sold 500 shares of the business's stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $325.00, for a total transaction of $162,500.00. Following the completion of the sale, the director directly owned 42,122 shares of the company's stock, valued at $13,689,650. This represents a 1.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In other Ligand Pharmaceuticals news, Director Jason Aryeh sold 3,000 shares of the company's stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $320.05, for a total transaction of $960,150.00. Following the completion of the sale, the director directly owned 105,476 shares in the company, valued at $33,757,593.80. This represents a 2.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Analysts Set New Price Targets

Several research firms have recently commented on LGND. Royal Bank Of Canada lifted their price objective on Ligand Pharmaceuticals from $345.00 to $357.00 and gave the stock an "outperform" rating in a report on Friday, October 30th. Weiss Ratings lowered Ligand Pharmaceuticals from a "buy (b)" rating to a "hold (c)" rating in a research note on Monday, November 2nd. Leerink Partners started coverage on Ligand Pharmaceuticals in a report on Friday, August 14th. They set an "outperform" rating and a $330.00 target price for the company. Barclays raised their price target on Ligand Pharmaceuticals from $345.00 to $350.00 and gave the stock an "overweight" rating in a research report on Wednesday, November 11th. Finally, Citigroup lifted their price target on Ligand Pharmaceuticals from $397.00 to $402.00 and gave the stock a "buy" rating in a research note on Thursday, November 5th. Eight research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, Ligand Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $355.38.

Check Out Our Latest Stock Analysis on LGND

Ligand Pharmaceuticals Trading Down 2.3%

The stock has a market capitalization of $6.03 billion, a P/E ratio of 134.69, a P/E/G ratio of 5.52 and a beta of 1.16. The firm's 50 day moving average price is $302.03 and its 200 day moving average price is $258.58. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.22 and a quick ratio of 1.19.

Ligand Pharmaceuticals (NASDAQ:LGND - Get Free Report) last posted its earnings results on Thursday, October 29th. The biotechnology company reported $2.67 earnings per share for the quarter, topping analysts' consensus estimates of $2.33 by $0.34. Ligand Pharmaceuticals had a net margin of 20.27% and a return on equity of 5.22%. The company had revenue of $78.75 million during the quarter, compared to analyst estimates of $77.00 million. During the same period in the prior year, the business posted $3.09 earnings per share. Ligand Pharmaceuticals's revenue for the quarter was down 31.8% on a year-over-year basis. As a group, equities research analysts expect that Ligand Pharmaceuticals Incorporated will post 2.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ligand Pharmaceuticals

A number of large investors have recently made changes to their positions in LGND. Cetera Investment Advisers increased its stake in shares of Ligand Pharmaceuticals by 2.5% during the third quarter. Cetera Investment Advisers now owns 3,833 shares of the biotechnology company's stock valued at $1,197,000 after buying an additional 95 shares during the period. Entropy Technologies LP bought a new position in shares of Ligand Pharmaceuticals during the third quarter valued at approximately $3,102,000. Pathstone Holdings LLC raised its holdings in shares of Ligand Pharmaceuticals by 57.2% during the third quarter. Pathstone Holdings LLC now owns 1,857 shares of the biotechnology company's stock valued at $580,000 after acquiring an additional 676 shares in the last quarter. Marshall Wace LLP purchased a new stake in Ligand Pharmaceuticals in the third quarter worth $9,904,000. Finally, AlphaGrep UK Ltd purchased a new stake in Ligand Pharmaceuticals in the third quarter worth $394,000. 91.28% of the stock is currently owned by institutional investors.

About Ligand Pharmaceuticals

(Get Free Report)

Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Ligand Pharmaceuticals Right Now?

Before you consider Ligand Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ligand Pharmaceuticals wasn't on the list.

While Ligand Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines